Nombre del producto:(R)-methyl2-((tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoate

IUPAC Name:methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-(diethoxyphosphoryl)propanoate

CAS:851475-17-7
Fórmula molecular:C13H26NO7P
Pureza:95%+
Número de catálogo:CM1018872
Peso molecular:339.33

Unidad de embalaje Stock disponible Precio($) Cantidad

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :851475-17-7
Fórmula molecular:C13H26NO7P
Punto de fusión:-
Código de sonrisas:CCOP(=O)(C[C@H](NC(=O)OC(C)(C)C)C(=O)OC)OCC
Densidad:
Número de catálogo:CM1018872
Peso molecular:339.33
Punto de ebullición:
Nº Mdl:
Almacenamiento:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Selatogrel
Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector).
This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death.